[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hodgkin-lymphoma-category\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hodgkin-lymphoma-category":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100586769","phase-2-phase-ii-trial-of-brecadd-in-hiv-positive-patients-with-advanced-stage-classical-hodgkin-lymphoma-100586769",false,"NCT06919679","Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma","BASTION","Inclusion Criteria:\n\n* Histologically confirmed first diagnosis of cHL\n* Advanced-stage disease: stage IIB with large mediastinal mass and\u002For extranodal lesions or stage III or IV\n* No previous treatment for HL with the exception of steroid prephase\n* Confirmed HIV infection with CD4 counts ≥ 150\u002FμL at registration or \\> 250\u002FμL at any time within 8 months prior to HL diagnosis\n* Continuation of antiretroviral treatment (ART) \u002F Initiation of ART in patients who are ART-naive\n* Age: 18-60 years\n\nExclusion Criteria:\n\n* Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma\n* Multi-drug resistant HIV infection or concurrent AIDS-defining conditions\n* Pregnancy or breastfeeding","ALL","18 Years","60 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET\u002FCT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.",[27],"Hodgkin Lymphoma (Category)",[29,30,31],"advanced stage","HIV positive","Brentuximab Vedotin","NOT_YET_RECRUITING","2025-04-02",{"date":35,"type":36},"2025-04-09","ACTUAL",{"date":38,"type":21},"2025-08",{"date":40,"type":21},"2030-01",{"name":42,"class":43},"University of Cologne","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100574640","phase-4-bv-in-the-treatment-of-relapsedrefractory-hodgkin-lymphoma-100574640","NCT06761911","BV in the Treatment of Relapsed\u002Frefractory Hodgkin Lymphoma","A Real-world Study of Brentuximab Vedotin Monotherapy and Combination Regimens in the Treatment of Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Histologically, classical hodgkin lymphoma（cHL） was diagnosed and relapsed or refractory.\n* Patients were treated with BV-containing regimen at least once\n* Presence of tumor (measurable or nonmeasurable).\n* Signature of the form consent for participation in the study.\n\nExclusion Criteria:\n\n* \\\u003C18 years",{"count":52,"type":21},100,[54],"PHASE4","The goal of this clinical trial is to explore the real-world Chinese relapsed\u002Frefractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are:\n\nTo evaluate the efficacy and toxicity of BV-containing regimen in relapsed\u002Frefractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.",[27],[31,58,59,60,61],"Hodgkin lymphoma","refractory recurrence","real world","china","2025-01-06",{"date":64,"type":36},"2025-01-07",{"date":66,"type":21},"2024-12-31",{"date":68,"type":21},"2026-01-31",{"name":70,"class":43},"Xiuhua Sun"]